Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pramiracetam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 5/20 | 0.44 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.44 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.44 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramiracetam SCHEMBL195465 | 0.99 | LMNA (0.48) | LMNAHTTTSHRADRA1DADRA1A | |
| Pramiracetam SCHEMBL11556360 | 0.97 | LMNA (0.47) | LMNAHTTTSHRADRA1DADRA1A | |
| Pramiracetam SCHEMBL1171471 | 0.96 | LMNA (0.46) | LMNAHTTTSHRADRA1DADRA1A | |
| Pramiracetam SCHEMBL120423 | 0.95 | LMNA (0.46) | LMNAHTTTSHRADRA1DADRA1A | |
| Pramiracetam SCHEMBL4431064 | 0.90 | LMNA (0.40) | LMNAHTTTSHRADRA1DADRA1A | |
| Pramiracetam SCHEMBL2136275 | 0.86 | LMNA (0.57) | LMNAHTTTSHRADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL11555232 | 0.85 | HTT (0.49) | LMNAHTTTSHRADRA1DADRA1A | |
| SCHEMBL8961554 | 0.84 | LMNA (0.45) | LMNAHTTTSHRADRA1DADRA1A | |
| SCHEMBL11553497 | 0.83 | HTT (0.50) | LMNAHTTTSHRADRA1DADRA1A | |
| SCHEMBL11554851 | 0.83 | TP53 (0.51) | LMNAHTTTSHRADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114118496-B | Method and system for automatically scheduling queuing reservation based on big data analysis | 四川恒升信达科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2023224790-A1 | SYSTEM AND METHOD FOR TWO-DIMENSIONAL ELECTRONIC DEVICES | MORAMPUDI MANICHANDRA (US) | 2023-11-23 | — | — | WO | claimed |
| CN-116747936-B | Steel slag jaw crushing and separating assembly, separating and treating system and molten steel slag treating method | 包钢集团节能环保科技产业有限责任公司 | 2023-10-17 | — | — | CN | claimed |
| CN-116747936-A | Steel slag jaw crushing and separating assembly, separating and treating system and molten steel slag treating method | 包钢集团节能环保科技产业有限责任公司 | 2023-09-15 | — | — | CN | claimed |
| EP-3609573-A1 | TRANSCUTANEOUS IRRADIATION DEVICE AND APPLICATION TO THE TREATMENT OF NEURODEGENERATIVE DISEASES | REGENLIFE (FR) | 2020-02-19 | — | — | EP | claimed |
| WO-2018189393-A1 | TRANSCUTANEOUS IRRADIATION DEVICE AND APPLICATION TO THE TREATMENT OF NEURODEGENERATIVE DISEASES | REGENLIFE (FR) | 2018-10-18 | — | — | WO | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1559310-A2 | Conservatory | Bär, Volker (DE) | 2005-08-03 | — | — | EP | claimed |
| WO-1996038080-A2 | HEART BEAT MEASUREMENT USING RADIOFREQUENCY LINK | BITTON PAUL ELIE (FR) | 1996-12-05 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-4461648-A | COOKING IN PRESSURIZED STEAM | IOGEN ENERGY CORPORATION (CA) | 1984-07-24 | — | — | US | disclosed |
| EP-0002403-A1 | Counting and dispensing closure for granules disposed in a container | LABORATOIRES SUPPO-STERIL Société à responsabilité limitée dite: (FR) | 1979-06-13 | — | — | EP | disclosed |
| US-4103847-A | Line scan area signature detection method | MARTIN MARIETTA CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
| US-4085224-A | SALINOMYCIN OR ITS SALTS | ELI LILLY AND COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | ADRA1D 2684/4885ADRA1A 2834/4885ADRA1B 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.